Patients to Trials Consortium

Research Areas

- Tool Development
- Clinical Trial
- Data-Sharing Enabler

At a Glance

- Status: Active Consortium
- Year Launched: 2013
- Initiating Organization: Eli Lilly
- Initiator Type: Industry
- Location: North America

Abstract

The Patients to Trials Consortium is a three-member pharmaceutical industry consortium that aims to provide a new platform to improve access to information about clinical trials for patients and providers. The platform aims to enhance the existing clinicaltrials.gov by providing more detailed and patient-friendly information about available trials and embedding a machine-readable “target health profile” to improve the ability of healthcare software to match individual health profiles with applicable clinical trials.

Mission

Using clinicaltrials.gov as its foundation and Eli Lilly’s Application Programming Interface (API), the Patients to Trials Consortium focuses on creating an open platform to make these data more amenable to patients and providers, as well as an opportunity to integrate a patient’s electronic health record (EHR) into the clinical trial matching service. This feature will allow patients to search for trials using their own Blue Button data.

The following features are planned add-ons to clinicaltrials.gov:
Consortium History

The first demonstration of the prototype was made available on June 2014, built on a database of anonymized patient health records from different clinical research studies sponsored by Lilly, Novartis, and Pfizer.

Intellectual Property

The platform is open-sourced and available to the public.

Data Sharing

The platform being built by the consortium will have the following data-sharing open features:

Impact/Accomplishment

June 2014: The Project Build phase was completed. A working version of the platform was developed and tested with the project team.

July 2014: Populating the content of the platform began, that is, developing, testing, and loading Target Profiles for approximately 50 clinical research studies at Novartis, Lilly, and Pfizer that were recruiting patients in the U.S. This was targeted to be available on the platform by the end of July 2014.

Summer/Fall 2014: Public domain testing of the platform began. The consortium actively sought partners who were willing and interested to test the platform and provide feedback on whether and how the platform helps them better inform patients (and their providers) about the opportunities they have to volunteer for clinical research studies, based on their Blue Button Plus health records.

Links/Social Media Feed

Homepage  https://sites.google.com/site/p2tconsortium/
Other website

http://portal.lillycoi.com/

Sponsors & Partners

Corengi
Eli Lilly and Co.
Novartis
Pfizer, Inc.

Updated: 04/08/2016